Clinical trials: Chronic Obstructive Pulmonary Disease, Unspecified
- Condition Chronic Obstructive Pulmonary Disease, Unspecified
- Funder type Industry (pharma, biotech, devices)
Chronic Obstructive Pulmonary Disease
Evaluating Forced Oscillation Technique (FOT) in Abolishing Flow Limitation
To validate the capability of the Respironics Synchrony ventilator to properly detect Expiratory Flow Limitation (EFL) as compared to the gold standard method of detecting EFL via the Mead and Wittenberger technique.
- Trial name
- NCT01151618
- Testing
- Respironics Synchrony ventilator (Non Invasive Ventilation)
- Where
- United Kingdom
- Volunteers
- 22 people
- Sponsor
- Philips Respironics
Pulmonary Disease, Chronic Obstructive
Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients
The primary objective of the present study is to evaluate the effect of tiotropium + olodaterol fixed dose combination (FDC) compared to tiotropium monotherapy on the intensity of breathlessness during the 3min constant speed…
- Trial name
- NCT02853123
- Testing
- Tiotropium, Olodaterol
- Where
- 13 sites in Belgium, Canada and 2 more
- Volunteers
- 106 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
A Pilot Study to Evaluate the ROX Anastomotic Coupler System in Patients With Chronic Obstructive Pulmonary Disease
The purpose of this study is to evaluate the safety and preliminary performance of the ROX Anastomotic Coupler System (ACS), with standard of care (as defined per GOLD) in patients with Chronic Obstructive Pulmonary Disease…
- Trial name
- NCT00992680
- Testing
- ROX Anastomotic Coupler System (ACS)
- Where
- 9 sites in United States
- Volunteers
- 49 people
- Sponsor
- ROX Medical, Inc.
Pulmonary Disease, Chronic Obstructive
SERETIDE 50/500mcg Versus Tiotropium Bromide On Exacerbation Rates In Severe Chronic Obstructive Pulmonary Disease
This is a comparator study to assess the relative efficacy of the combination product fluticasone propionate/salmeterol 50/500 and tiotropium bromide on the rate of exacerbations of chronic obstructive pulmonary disease (COPD)…
- Trial name
- NCT00361959
- Testing
- Tiotropium bromide 18mcg, Fluticasone propionate/ salmeterol combination 50/500mcg
- Where
- 166 sites in Austria, Belgium and 18 more
- Volunteers
- 1,270 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease
This study will assess the efficacy, tolerability and safety of NVA237 compared to tiotropium when added on to fluticasone/salmeterol in patients with chronic obstructive pulmonary disease.
- Trial name
- NCT01513460
- Testing
- NVA237 50µg once daily, Tiotropium 18µg once daily, Flu/Sal
- Where
- 71 sites in Australia, New Zealand
- Volunteers
- 773 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This is a multicenter, randomized, double-blind, double-dummy, parallel group study. The purpose of this study is to compare the efficacy and safety of umeclidinium/vilanterol (UMEC/VI) and fluticasone propionate/salmeterol (FSC)…
- Trial name
- NCT01817764
- Testing
- Umeclidinium/vilanterol, Fluticasone propionate/salmeterol
- Where
- 59 sites in United States, Argentina and 5 more
- Volunteers
- 707 people
- Sponsor
- GlaxoSmithKline
COPD
A Dose Ranging Study of Arformoterol Given Once Daily Compared to Arformoterol Given Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A dose ranging study to evaluate the safety, tolerability and efficacy of arformoterol (given once or twice a day) in subjects with COPD.
- Trial name
- NCT00691405
- Testing
- Arformoterol tartrate inhalation solution
- Where
- 31 sites in United States
- Volunteers
- 215 people
- Sponsor
- Sumitomo Pharma America, Inc.
Pulmonary Disease, Chronic Obstructive
A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic Obstructive Pulmonary Disease (COPD) Using a Novel Dry Powder Inhaler (NDPI)
Studies to date provides substantial evidence for the effectiveness for UMEC 62.5 microgram (mcg) as a long term maintenance therapy for the treatment of COPD; this study further evaluates the efficacy and safety of UMEC 62.5 mcg…
- Trial name
- NCT02184611
- Testing
- Umeclidinium bromide
- Where
- 26 sites in China, South Korea
- Volunteers
- 308 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry II
To compare the effects of BI 1744 CL versus placebo on exercise tolerance after 6 weeks of treatment in patients with Chronic Obstructive Pulmonary Disease.
- Trial name
- NCT01040793
- Testing
- Olodaterol (BI 1744), Olodaterol (BI1744)
- Where
- 19 sites in Austria, Belgium and 3 more
- Volunteers
- 157 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
The AIRWARD Study: A Study to Test Whether Verducatib Helps People With Chronic Obstructive Pulmonary Disease
This study is open to adults aged 40 years and older who have chronic obstructive pulmonary disease (COPD) with ongoing symptoms.
- Trial name
- NCT07907991
- Testing
- Verducatib
- Volunteers
- 1,800 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
This study assessed the safety/tolerability of 28 days of treatment with NVA237 100 µg and 200 µg once a day, compared to placebo in patients with moderate or severe Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT00510510
- Testing
- NVA237 100 µg, NVA237 200 µg
- Where
- 21 sites in United States, France and 4 more
- Volunteers
- 281 people
- Sponsor
- Novartis
Chronic Obstructive Pulmonary Disease
AZD9668 Relative Bioavailability
The study is designed to investigate the pharmacokinetic behaviour of the free base formulation of AZD9668. The study will compared the relative bioavailability of the free base formulation at two different dose levels compared…
- Trial name
- NCT01034982
- Testing
- AZD9668
- Where
- Germany
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Asthma, Chronic Obstructive Pulmonary Disease
Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of ARO-MUC5AC in normal healthy volunteers (NHVs), patients with moderate-to-severe asthma and patients with moderate-to-severe chronic…
- Trial name
- NCT05292950
- Testing
- ARO-MUC5AC
- Where
- 13 sites in Australia, New Zealand and 5 more
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs.
GSK961081 is a potent dual pharmacophore that demonstrates both antimuscarinic and beta-agonist pharmacology in preclinical studies, both pharmacologies being of long duration.
- Trial name
- NCT00674817
- Testing
- 400 microgrammes GSK961081, 1200 microgrammes GSK961081
- Where
- 4 sites in New Zealand, Thailand and 1 more
- Volunteers
- 45 people
- Sponsor
- Theravance Biopharma
COPD
Tiotropium/Formoterol Via Discair® vs Tiotropium Monotherapy or Tiotropium + Formoterol Free Combination Treatment
The overall objective is to asses the bronchodilator effect of once daily Tiotropium/Formoterol combination delivered via Discair® by comparing Tiotropium (q.d.) monotherapy delivered via Handihaler and tiotropium (q.d.)…
- Trial name
- NCT02988869
- Testing
- Tiotropium/Formoterol, Tiotropium, Formoterol
- Where
- Turkey (Türkiye)
- Volunteers
- 84 people
- Sponsor
- Neutec Ar-Ge San ve Tic A.Ş
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Evaluate the Effects of BGF and GFF on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD
This is a randomised, controlled, two period cross-over, 4 weeks chronic dosing, study to evaluate the effects of Budesonide/Glycopyrronium/Formoterol Fumarate (BGF) and Glycopyrronium/Formoterol Fumarate (GFF) on airway…
- Trial name
- NCT03836677
- Testing
- BGF, GFF
- Where
- 4 sites in Belgium, Netherlands
- Volunteers
- 23 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
A Study on the Control of Chronic Obstructive Pulmonary Disease (COPD) in Patients Taking the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler
Open-label observational study which includes COPD patients that are receiving treatment with Spiolto® Respimat® for approximately 6 weeks, which is the average time between two medical consultations.
- Trial name
- NCT03663569
- Testing
- Spiolto® Respimat®
- Where
- 388 sites in Bulgaria, Czechia and 9 more
- Volunteers
- 4,819 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Effect of Umeclidinium (UMEC) as Combination Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
This is a multicenter, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of the addition of UMEC (62.5 microgram[mcg]) when administered once-daily via dry powder inhaler (DPI) to Inhaled…
- Trial name
- NCT02257372
- Testing
- UMEC DPI, ICS/LABA medication, Albuterol/salbutamol Metered Dose Inhaler (MDI)
- Where
- 28 sites in Czechia, Germany and 2 more
- Volunteers
- 236 people
- Sponsor
- GlaxoSmithKline
Lung Cancer Diagnosis
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
The PROACT LUNG study is a prospective multi-center observational study to validate a blood-based test for the early detection of lung cancer by collecting blood samples from high-risk participants who will undergo a routine…
- Trial name
- PROACT-LUNG (NCT06122077)
- Testing
- blood draw
- Where
- 36 sites in United States
- Volunteers
- 20,000 people
- Sponsor
- Freenome Holdings Inc.
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Aclidinium Bromide at Two Dose Levels Versus Placebo Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients
The main purpose of this study is to assess the long term bronchodilator efficacy, safety and tolerability of inhaled aclidinium bromide at two dose levels compared to placebo in COPD patients and the benefits of the product in…
- Trial name
- NCT01001494
- Testing
- Aclidinium bromide 200 μg bid, Aclidinium bromide 400 μg bid
- Where
- 106 sites in Czechia, France and 9 more
- Volunteers
- 828 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.